Research on Changes in Intestinal Barrier Function and Gut Microbiome in Patients With Type 2 Diabetes After Duodenal Mucosal Resurfacing (DMR) - Trial NCT06385704
Access comprehensive clinical trial information for NCT06385704 through Pure Global AI's free database. This phase not specified trial is sponsored by Wang Siqi and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wang Siqi
China-Japan Friendship Hospital
Timeline & Enrollment
N/A
Jun 01, 2024
Dec 01, 2025
Primary Outcome
Microbiome Analysis,High Performance Liquid Chromatography
Summary
The aim of this study is to demonstrate the effects of duodenal mucosal resurfacing (DMR) on
 intestinal barrier function and gut microbiota when treating uncontrolled type 2 diabetes.
 Subjects who underwent DMR and those who did not were enrolled, and potential differences
 were identified by analyzing urine and fecal samples through microbiotic analysis and High
 Performance Liquid Chromatography (HPLC), combined with changes in clinical data.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06385704
Non-Device Trial